Symbols

STXS

Stereotaxis·AMEX

--(--)

STXS fundamentals

STXS Q4 2025 Earnings

Stereotaxis (STXS) released its earnings on Mar 9, 2026: revenue was 8.64M (YoY +36.31%), missed estimates; EPS was -0.06 (YoY +33.33%), beat estimates.

Revenue / YoY

8.64M

+36.31%

EPS / YoY

-0.06

+33.33%

Report date

Mar 9, 2026

STXS Earnings Call Summary for Q4,2025

Strategic Shift: Transitioning to a $5,000/procedure disposable model from $1,000, with MAGiC production ramping to 500/month.
Regulatory Wins: FDA/CE approvals for GenesisX, MAGiC, and MAGiC Sweep; Synchrony FDA clearance imminent.
2026 Revenue Guidance: $40M+ annual revenue, with Q4 >$10M driven by MAGiC and Synchrony sales.
Manufacturing Progress: MAGiC production resolved; GenesisX capacity to scale to several dozen/year.
China Expansion: Genesis sales via MicroPort; MAGiC regulatory submissions pending.

Earnings

EPS

Revenue

Revenue & Expenses

STXS has released its 2025 Q4 earnings report, with revenue of 8.64M, reflecting a YoY change of 36.31%, and net profit of -5.53M, showing a YoY change of 26.40%. The Sankey diagram below clearly presents STXS's revenue sources and cost distribution.

Key Indicators

Stereotaxis (STXS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Stereotaxis (STXS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Stereotaxis (STXS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Stereotaxis (STXS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown